Patrick Lamy, Senior VP, Commercial Strategy at Akero Therapeutics, Inc. (AKRO), sold 16,000 shares at $42.76 ($680K) on 2025-05-07, disclosed to the SEC on 2025-05-09.
Scheduled sale ($680k) by Senior VP, Commercial Strategy under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.31 | 4,701 | $199K | 29.3% |
| 2 | $42.31 | 4,701 | $199K | 29.3% |
| 3 | $42.76 | 3,299 | $141K | 20.7% |
| 4 | $42.76 | 3,299 | $141K | 20.7% |
| Total | $42.50 avg | 16,000 | $680K | 100% |
| Filing → |
| AKRO | SELL | 2025-06-20 | $108K | — | Filing → |
| AKRO | SELL | 2025-06-12 | $50K | — | Filing → |
| AKRO | SELL | 2025-06-04 | $201K | — | Filing → |